LIQUIDIA CORP. DL-001
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The comp… Read more
LIQUIDIA CORP. DL-001 (LT4) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, LIQUIDIA CORP. DL-001 (LT4) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
LIQUIDIA CORP. DL-001 - Net Assets Trend (None–None)
This chart illustrates how LIQUIDIA CORP. DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LIQUIDIA CORP. DL-001 (None–None)
The table below shows the annual net assets of LIQUIDIA CORP. DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to LIQUIDIA CORP. DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
LIQUIDIA CORP. DL-001 Competitors by Market Cap
The table below lists competitors of LIQUIDIA CORP. DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Topaz Energy Corp
PINK:TPZEF
|
$1.90 Billion |
|
Neogen Corporation
NASDAQ:NEOG
|
$1.90 Billion |
|
MDA Ltd
PINK:MDALF
|
$1.91 Billion |
|
Eagers Automotive Ltd
AU:APE
|
$1.91 Billion |
|
Shenyang Fortune Precision Equipment Co. Ltd. A
SHG:688409
|
$1.90 Billion |
|
Weifu High-Technology Group Co Ltd
SHE:000581
|
$1.90 Billion |
|
Paycor HCM Inc
NASDAQ:PYCR
|
$1.90 Billion |
|
Marex Group plc Ordinary Shares
NASDAQ:MRX
|
$1.90 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LIQUIDIA CORP. DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares LIQUIDIA CORP. DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently LIQUIDIA CORP. DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares LIQUIDIA CORP. DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LIQUIDIA CORP. DL-001 (LT4) | €- | N/A | N/A | $1.90 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |